Abstract: Broad-based, cross-protective, O-serotype independent vaccines against Shigella and related pathogenic organisms are provided. The vaccines comprise one or more of the type III secretion (TTS) apparatus needle proteins IpaD and IpaB, and/or the IpaB cognate chaperone protein IpgC. Chimeric proteins of IpaD and IpaB, and/or IpgC are also encompassed.
Type:
Grant
Filed:
December 10, 2012
Date of Patent:
November 15, 2016
Assignee:
THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY
Abstract: The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic ehrlichiosis.
Type:
Grant
Filed:
August 1, 2014
Date of Patent:
October 18, 2016
Assignee:
ABAXIS, INC.
Inventors:
Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile
Abstract: A nanoantibody specifically binding surface antigen of Chlamydia trachomatis and having SEQ ID NO:2 amino acid sequence is disclosed. A nanoantibody specifically binding surface antigen of Chlamydia trachomatis and having SEQ ID NO:4 amino acid sequence is disclosed. A nanoantibody with SEQ ID NO:2 amino acid sequence inhibits development of Chlamydia infection caused by C. trachomatis. A nanoantibody with SEQ ID NO:4 amino acid sequence inhibits development of Chlamydia infection caused by C. trachomatis. A method of in vitro inhibiting a Chlamydia infection caused by C. trachomatis has the steps of pretreating elementary bodies of C. trachomatis by a therapeutically efficient amount of a nanoantibody specifically binding to a surface antigen of Chlamydia trachomatis, the nanoantibody comprising an amino acid sequence SEQ ID NO: 4 or SEQ ID NO:4, and then adding the elementary bodies of C. trachomatis to target cells being infected.
Type:
Grant
Filed:
July 18, 2014
Date of Patent:
October 11, 2016
Assignee:
Obschestvo s ogranichennoi otvetstvennostyu “Tekhnopharma”
Inventors:
Nailya A. Zigangirova, Sergey V. Tillib
Abstract: The present invention includes a method and device for the isolation of lymphocytes, particularly splenic lymphocytes, for administration to patients. In particular for patients undergoing a splenectomy, administration of splenic lymphocytes may increase a patient's immunity and reduce the likelihood of post-splenectomy infections and other complications.
Abstract: The present invention is directed to the use of FGK-1 immunopotentiator, composed by the peptide named GK-1, characterized by the sequence G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A (SEQ ID No. 1) and linked to the pVIII surface protein of M13 filamentous phage, to prepare pharmaceutical products potentiating the protective immune response of vaccine antigens when used by itself or conjointly with these antigens administered either intranasally, subcutaneously, or intramuscularly, yielding an increase in the level of specific antibodies against vaccine antigens in serum and in bronchioalveolar lavages.
Type:
Grant
Filed:
July 28, 2012
Date of Patent:
September 20, 2016
Assignee:
UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO
Inventors:
Edda Lydia Sciutto Conde, Gladis del Carmen Fragoso Gonzalez, René Alvaro Segura Velázquez, Jacquelynne Brenda Cervantes Torres, Karen Manucharyan, Abel Blancas Cabrera, Rutilia Marisela Hernandez Gonzales
Abstract: The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus Chlamydomonas, e.g., Chlamydomonas reinhardtii; the immunogenic Plasmodium polypeptides produced and compositions comprising them; and methods for preventing, ameliorating, reducing, delaying, treating and blocking the transmission of malaria by administration of immunogenic Plasmodium polypeptides produced in an algal host cell.
Type:
Grant
Filed:
May 1, 2012
Date of Patent:
August 23, 2016
Assignee:
The Regents of the University of California
Inventors:
Stephen P. Mayfield, James A. Gregory, Carla S. Jones, Michael J. Hannon
Abstract: The invention provides a new lactic acid bacteria (LAB) strain with immunomodulatory and anti-inflammatory activity and a composition containing and method using the same. The LAB of the invention can be administrated for modulating an immune response in order to restore or prevent metabolic disorders caused by obesity or chronic inflammation.
Abstract: The present disclosure relates to devices and methods for rapidly detecting streptococcus bacteria. An illustrative device includes a first elongate handle connected to a first edible portion and a second elongate handle connected to a second edible portion. The first and second elongate handles are connected by a banding material. The first and second edible portions are inserted into the mouth of an individual for receiving a saliva sample.
Abstract: Problem to be Solved: The present invention provides a novel mucosal adjuvant. Solution: The present invention provides a mucosal adjuvant composition containing at least a composition comprising molecules having a molecular weight in a range of 100 to 300 kDa obtained from cells or culture fluid of Bordetella bronchiseptica. Administration of the mucosal adjuvant composition to a non-human animal at a surface of the mucous membrane can enhance immunity at the surface of mucous membrane. Therefore preventive effects against trans-mucosal infection can be increased by administering an inactivated vaccine against trans-mucosal infection and the mucosal adjuvant composition to a non-human animal at a surface of mucous membrane. The present invention is effective for preventing trans-mucosal infections, including one or more infections of e.g., canine parainfluenza, canine adenovirus, canine coronavirus, canine parvovirus, canine distemper virus, canine herpesvirus, reovirus and pneumovirus.
Abstract: The present invention relates to a recombinant protein comprising SEQ ID NO: 1 and a bacteria recognizing lectin. The present invention also relates to uses of the recombinant protein comprising detecting pathogens, removing endotoxins, determining the presence of an endotoxin or endotoxin-like material, and determining the presence of pathogen-associated molecular pattern (PAMP) comprising rhamnose-rhamnose (Rha-Rha), rhamnose-N-acetyl-mannosamine (Rha-ManNAc), N-acetyl-mannosamine-rhamnose (ManNAc-Rha), rhamnose-galatose (Rha-Gal), or galatose-rhamnose (Gal-Rha) in a sample, and use as a medicament, a disinfectant, a decontaminant, a surfactant or a diagnostic means.
Type:
Grant
Filed:
May 13, 2014
Date of Patent:
May 3, 2016
Assignee:
SIMPSON BIOTECH CO., LTD.
Inventors:
Margaret Dah-Tsyr Chang, Chia-Chin Sheu
Abstract: The inventive subject matter relates to a recombinant polypeptide construct comprising enterotoxigenic Escherichia coli fimbrial subunits. The recombinant polypeptide constructs comprise multiple subunits to the same or different ETEC fimbrial types. The constructs are useful for inclusion in immunogenic formulations for the inductin of immunity against entertoxigenic Escherichia coli. The inventive subject matter also relates to the use of the recombinant polypeptide constructs in induce anti-enterotoxigenic Escherichia coli.
Type:
Grant
Filed:
October 8, 2013
Date of Patent:
May 3, 2016
Assignee:
The United States of America as represented by the Secretary of the Navy
Abstract: The invention relates to a novel solubilized small molecule topical formulation for the transdermal delivery of small molecule agents comprising: a small molecule agent, one or more micelle forming compounds, one or more skin penetration enhancers, a surfactant, and one or more solvents, wherein the small molecule agent is solubilized in the solvent. The invention further relates to the use of the topical formulation as well as the process for making the topical formulation.
Abstract: The invention relates to a novel solubilized benzoyl peroxide topical formulation for the treatment of acne comprising: benzoyl peroxide, one or more micelle forming compounds, one or more skin penetration enhancers, a surfactant, and one or more solvents, wherein the benzoyl peroxide is solubilized in the solvent. The invention further relates to the use of the topical formulation as well as the process for making the topical formulation.
Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.
Type:
Grant
Filed:
January 31, 2012
Date of Patent:
April 12, 2016
Assignee:
National Research Council of Canada
Inventors:
Wei-Gang Hu, Laurel M Negrych, Damon Chau, Junfei Yin, Scott J. Jager, John W. Cherwonogrodzky
Abstract: The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.
Type:
Grant
Filed:
December 20, 2013
Date of Patent:
March 1, 2016
Assignee:
Boehringer Ingelheim Vetmedica GmbH
Inventors:
Dianna M. Murphy Jordan, Brian Thomas Martinson, Christine Margaret Muehlenthaler, Axel Neubauer, Arun V. Iyer
Abstract: The present invention relates to a new strain of Lactobacillus delbrueckii subsp. bulgaricus, suitable for use in the treatment or prevention of Helicobacter pylori infection.
Type:
Grant
Filed:
August 9, 2011
Date of Patent:
March 1, 2016
Assignee:
Compagnie Gervais Danone
Inventors:
Peggy Garault, Gaelle Quere, Raphaelle Bourdet-Sicard, Francis Megraud
Abstract: The present application relates to a composition including gut flora-derived extracellular vesicles, and to an animal disease model using same. In addition, the present application relates to a method for using the gut flora-derived extracellular vesicles to efficiently search for a candidate drug which may prevent or treat diseases that occur due to gut flora-derived extracellular vesicles, and to a vaccine which can efficiently prevent or treat infections caused by gut flora or diseases that occur due to gut flora-derived extracellular vesicles. Further, the development of diagnostic technology to discover, using the gut flora-derived extracellular vesicles of the present application, the etiology of diseases that occur due to gut flora-derived extracellular vesicles, can be achieved.
Type:
Grant
Filed:
July 2, 2014
Date of Patent:
March 1, 2016
Assignee:
Aeon Medix Inc.
Inventors:
Yoon Keun Kim, Yong Song Gho, Kyoung Su Park, Bok Sil Hong, Ji Hyun Kim, You Sun Kim, Won Hee Lee, Jung Wook Kim, Dae-Kyum Kim
Abstract: The invention provides novel strains Agrobacterium tumefaciens KKP 2039p and Paracoccus alcaliphilus KKP 2040p, the plasmid pSinA and its functional derivative, method for producing bacterial strains capable of chemolithotrophic arsenite oxidation and novel bacterial strains produced by this method. The invention also relates to the composition, comprising the novel bacterial strain or the plasmid pSinA and the use of these novel strains, as well as the method of bioaugmentation of an arsenic contaminated environment, particularly the method for the removal of arsenic from waters.
Type:
Grant
Filed:
February 4, 2015
Date of Patent:
January 26, 2016
Assignee:
UNIWERSYTET WARSZAWSKI
Inventors:
Lukasz Drewniak, Aleksandra Sklodowska, Monika Radlinska, Martyna Ciezkowska
Abstract: The present invention relates to rodenticides, methods of killing a rodent comprising administering to said rodent, a lethal dose of an isolated Yersinia murine toxin polypeptide or an isolated antigenic analogue thereof, and methods of manufacturing novel rodenticides.
Type:
Grant
Filed:
November 10, 2008
Date of Patent:
December 29, 2015
Assignee:
The Secretary of State for Defense
Inventors:
Petra Claire Farquhar Oyston, Graeme Christopher Clark